These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36629737)

  • 1. Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.
    Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Blank K; Grinnan D; Holmes JH; Mathai SC; Minhas J; Ventetuolo CE; Zamanian RT; Kawut SM
    Am J Respir Crit Care Med; 2023 Apr; 207(8):1070-1079. PubMed ID: 36629737
    [No Abstract]   [Full Text] [Related]  

  • 2. Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.
    Ventetuolo CE; Moutchia J; Baird GL; Appleby DH; McClelland RL; Minhas J; Min J; Holmes JH; Urbanowicz RJ; Al-Naamani N; Kawut SM
    Ann Am Thorac Soc; 2023 Jan; 20(1):58-66. PubMed ID: 36053665
    [No Abstract]   [Full Text] [Related]  

  • 3. Electrocardiographic Abnormalities and Their Association with Outcomes in Randomized Clinical Trials of Pulmonary Arterial Hypertension.
    Minhas J; Moutchia J; Al-Naamani N; Mazurek JA; Holmes JH; Appleby D; Smith KA; Fritz JS; Pugliese SC; Palevsky HI; Kawut SM
    Ann Am Thorac Soc; 2024 Jun; 21(6):858-865. PubMed ID: 38241602
    [No Abstract]   [Full Text] [Related]  

  • 4. BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
    McCarthy BE; McClelland RL; Appleby DH; Moutchia JS; Minhas JK; Min J; Mazurek JA; Smith KA; Fritz JS; Pugliese SC; Urbanowicz RJ; Holmes JH; Palevsky HI; Kawut SM; Al-Naamani N
    Chest; 2022 Aug; 162(2):436-447. PubMed ID: 35247393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank).
    Charoenpong P; Dhillon N; Murnane K; Goeders N; Hall N; Keller C; Bhuiyan MAN; Walter R
    BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38061804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension.
    Huang J; Mehta S; Mura M
    Respiration; 2015; 89(5):365-73. PubMed ID: 25791910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP).
    Stollfuss B; Richter M; Drömann D; Klose H; Schwaiblmair M; Gruenig E; Ewert R; Kirchner MC; Kleinjung F; Irrgang V; Mueller C
    J Med Internet Res; 2021 Oct; 23(10):e25163. PubMed ID: 34623313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
    Pan HM; McClelland RL; Moutchia J; Appleby DH; Fritz JS; Holmes JH; Minhas J; Palevsky HI; Urbanowicz RJ; Kawut SM; Al-Naamani N
    Eur Respir J; 2023 Jul; 62(1):. PubMed ID: 37169384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.
    Savarese G; Paolillo S; Costanzo P; D'Amore C; Cecere M; Losco T; Musella F; Gargiulo P; Marciano C; Perrone-Filardi P
    J Am Coll Cardiol; 2012 Sep; 60(13):1192-201. PubMed ID: 22995024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
    Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease.
    Holland AE; Hill CJ; Rasekaba T; Lee A; Naughton MT; McDonald CF
    Arch Phys Med Rehabil; 2010 Feb; 91(2):221-5. PubMed ID: 20159125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
    Nathan SD; du Bois RM; Albera C; Bradford WZ; Costabel U; Kartashov A; Noble PW; Sahn SA; Valeyre D; Weycker D; King TE
    Respir Med; 2015 Jul; 109(7):914-22. PubMed ID: 25956020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.
    Mathai SC; Puhan MA; Lam D; Wise RA
    Am J Respir Crit Care Med; 2012 Sep; 186(5):428-33. PubMed ID: 22723290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.
    Sanges S; Launay D; Rhee RL; Sitbon O; Hachulla É; Mouthon L; Guillevin L; Rottat L; Montani D; De Groote P; Cottin V; Magro P; Prévot G; Bauer F; Bergot E; Chabanne C; Reynaud-Gaubert M; Leroy S; Canuet M; Sanchez O; Gut-Gobert C; Dauphin C; Pison C; Boissin C; Habib G; Clerson P; Conesa F; Cordier JF; Kawut SM; Simonneau G; Humbert M
    Ann Rheum Dis; 2016 Aug; 75(8):1457-65. PubMed ID: 26324844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Placebo Effect beyond Regression to the Mean on the Six Minute Walk Test in Pulmonary Arterial Hypertension Trials.
    Anheyer D; Bugaj TJ; Lüdtke R; Appelbaum S; Trübel H; Ostermann T
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States.
    Divers C; Platt D; Wang E; Lin J; Lingohr-Smith M; Mathai SC
    J Manag Care Spec Pharm; 2017 Jan; 23(1):92-104. PubMed ID: 28025931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.